New Grant Awardees

The Carver College of Medicine Office of Scientific Affairs wishes to congratulate our Principal Investigators who have been awarded funding during the month of May

Name Department Funding Agency Title
Tucker, Robert Pathology Medical Murray, Inc. Minimally Invasive Tissue Tightening Device
Packer, Hans Psychiatry Nellie Ball Trust A Mammalian Model of a Gene Variant that is a Risk Factor for Schizophrenia
Ho, Beng Choon Psychiatry Nellie Ball Trust A Magnetic Resonance Spectroscopy Study of Young, Nonpsychotic Siblings of Schizophrenia Patients
Anderson, Michael Physiology & Biophysics Knights Templar Eye Foundation, Inc. New Genetic Pathways of Congenital Glaucoma
Goldman, Frederick Pediatrics Talecris Biotherapeutics Immunomodulatory Properties of IGIV in Developing Immune Systems Post Hematopoietic Stem Cell Transplant
Fingert, John Ophthalmology & Visual Sciences American Glaucoma Society Molecular Genetics of Pigment Dispersion Syndrome
Chaloupka, John Radiology Boston Scientific Corporation MAPS Trial: Matrix and Platinum Science: A Prospective, Randomized, Multicenter Trial Investigating Matrix2tm and GDC Coils for the Treatment of Intracranial Saccular Aneurysms
Song, Long-Sheng Internal Medicine American Heart Association Defective Local Excitation-Contraction Coupling in Heart Failure
Brennan, Timothy Anesthesia Painceptor Pharma Corporation Painceptor Service Agreement
Fredericks, Douglas Orthopaedics and Rehabilitation Electro-Biology, Inc. Assessment of Biomet Ultrasound System (BUSS) Fresh Fracture Healing Device in a Rabbit Fibular Osteotomy Model: 21 Day Study Period
Fasano, Mary Internal Medicine American College of Allergy, Asthma & Immunology The ACAAI Clinical Fellowship Stipend in Allergy and Immunology
Hoballah, Jamal Surgery Sanofi Aventis Groupe A Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial of HMR1766 Assessing the Efficacy and Safety of 3 doses of HMR1766 (25, 100, 200 mg OD) versus Placebo with Cilostazol, 100 mg BID as a Calibrator, Administered for 26 Weeks in Patients with Peripheral Arterial Disease (PAD), Fontaine Stage II
Amendola, Annunziato Orthopaedics and Rehabilitation American Orthopaedic Society for Sports Medicine Non-Invasive Assessment of Cartilage Health: A New Approach with T1rho MRI
Link, Brian Internal Medicine Eli Lilly & Company A Phase 3 Clinical Study to Investiage the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Davidson, Beverly Internal Medicine National Institutes of Health RNAi for Dominant Neurological Disease P01
Wilkinson, Neal Surgery NSABP Foundation, Inc. Addendum to NSABP TIND for Subpart NSABP B-40-ROCHE and Subpart NSABP LTS-01 - UCLA
Hoffman, Eric Radiology Marval Therapeutics, Inc. Liposomal Contrast Agent Assessment
Dornfeld, Kenneth Radiation Research Laboratory National Institutes of Health Mitochondrial Oxidative Stress in Thymineless Death
Winokur, Patricia Internal Medicine Saint Louis University IMVAMUNE Smallpox Vaccine Trial
Strack, Stefan Pharmacology National Institutes of Health Regulation of Mitochondrial Fission/Fusion by PP2A and PKA in Neurons
Martin, Brian Microbiology National Institutes of Health Complement Protection and Anaphylatoxins in Neuroinflammation
Magnotta, Vincent Radiology National Institutes of Health BRAINS Morphology and Image Analysis
Nauseef, William Internal Medicine National Institutes of Health Biosynthesis, Structural Organization, and Function of NOX Proteins
Kusner, David Internal Medicine Vertex Pharmaceuticals, Inc. Proposal for the Development of Novel Kinase Inhibitor Treatments for Mycobacterium tuberculosis Infection
Sheffield, Val Pediatrics National Institutes of Health Interdisciplinary Approach to Retinal Disease Gene Identification
Paulsen, Jane Psychiatry National Institutes of Health Cognitive and Functional Brain Changes in Preclinical Huntington's Disease (HD)
Johnson, Hans Psychiatry National Institutes of Health Enterprise Storage in a Collaborative Neuroimaging Environment
Schmidt, Warren Internal Medicine Human Genome Sciences, Inc. A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNα2a) in Combination with Ribavirin in Interferon Alfa Naïve Subjects with Chronic Hepatitis C Genotype 1: ACHIEVE-1
Cram, Peter Internal Medicine National Institutes of Health Cardiac Care in Specialty and General Hospitals